THE POWER OF fomorrow

Engaging the TCR to Transform the Treatment of Solid Tumors

Corporate Presentation May 2022



Forward Looking Statements

This presentation has been prepared by TCR² Therapeutics Inc. ("we," "us," or "our") and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our clinical results and other future conditions. All statements, other than statements of historical facts, contained in this presentation, including express or implied statements regarding our expectations for the Phase 2 clinical trial of gavo-cel and the Phase 1/2 clinical trial of TC-510, including expected progress and timing of updates; our expectations for the safety and efficacy of, and enhancements to, gavo-cel, TC-510 and our other product candidates including compared to other T-cell therapy approaches; our expectations regarding the estimated patient populations and related market opportunities in gavo-cel's, TC-510's and our other product candidates' targeted indications; our expectations regarding manufacturing of gavo-cel, TC-510 and our other product candidates; our expectations regarding our development programs and IND-enabling studies; our expectations regarding expansion opportunities for our TRuC platform; and our expectations regarding our financial position are forward-looking statements. These statements are based on management's current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.


Such risks and uncertainties include, among others: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of a trial; the possibility that positive results from preclinical studies and correlative studies may not necessarily be predictive of the results of our planned clinical trials, including the Phase 2 clinical trial of gavo-cel and Phase 1/2 clinical trial of TC-510; the risk that the results from

the Phase 2 clinical trial of gavo-cel and Phase 1/2 clinical trial of TC-510 will not support further development and marketing approval; the risk that we may be unable to gain approval of gavo-cel, TC-510 and our other product candidates on a timely basis, if at all; the risk that we have over-estimated the potential patient population for our product candidates, if approved; the risk that the current COVID-19 pandemic will impact our clinical trials and other operations; and the other risks set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 22, 2022, as updated in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the SEC on May 15, 2022, and in our future filings with the SEC available at the SEC's website at www.sec.gov. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made.

While we may elect to update these forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.



Innovating the Natural Power of the TCR for Solid Tumors



(T Cell Receptor Fusion Construct)

We Are Solving the Translation of Cell Therapies to Solid Tumors with a New Modality: TRuC-T Cells



Comprehensive T cell activation through integration with full TCR complex



No HLA restriction supports broad patient access



Versatile platform with flexibility to add enhancements



Multiple high-value indications across oncology and autoimmune



Where We Are Going

TCR²'s 2022 Trajectory and Beyond

Innovation, Execution & Impact Emerging Pipeline Balancing Breadth and Speed-to-Market Multiple Targets: MSLN, CD70, GPC3, NECTIN-4 Creating Significant Opportunities in Solid Tumors Novel Enhancements: PD-1 Switch, IL-15, and More Expansion in Autoimmune Targets **TRuCs: A Superior Modality Mesothelin Franchise Building Manufacturing Capacity** Industry Leader in Targeting Mesothelin Initial Production by CDMOs No HLA Restriction Autologous & Allogeneic Programs Two Suites at ElevateBio BaseCamp High Patient Eligibility Rate Two Clinical Programs: gavo-cel + TC-510 Establishing Manufacturing Center of Excellence Versatile Platform using Full TCR Complex **Broad Target Populations** in Rockville, MD



Advancing a Diverse Pipeline of Solid Tumor Programs

Target	Indication(s)	Program	Enhancement / Combo	Discovery	Lead Optimization	IND Enabling	Phase 1/2	Phase 2/3
Oncology								
Autologous								
MSLN	Ovarian cancer, NSCLC, MPM, Cholangiocarcinoma	gavo-cel						
MSLN	Ovarian cancer, NSCLC, MPM, Cholangiocarcinoma	gavo-cel	Checkpoint inhibitor					
MSLN	Solid tumors	TC-510	PD-1 switch					
CD70	Renal cell carcinoma	TC-520	IL-15					
GPC3	Solid tumors							
Nectin-4	Solid tumors							
Allogeneic								
MSLN	Solid tumors	gavo-cel	IL-15 / PD-1 switch					
CD70	Renal cell carcinoma	TC-520	IL-15 / PD-1 switch					
Autoimmune								
Autologous								
HLA-A*02	Solid organ transplant / GvHD							




Leading the Way with gavo-cel

Stage of Development: Phase 2



The Significant Mesothelin Solid Tumor Market

~215,000 Patients Across Multiple Target Indications




Indication		Population	MSLN Expression	Program(s)	POC	
	МРМ	1,800	76%	gavo-cel TC-510	Orphan Drug Designation 4 PRs (3 RECIST PRs) 5.9 mPFS (months) 11.2 mOS (months)	
	Ovarian Cancer	12,400	58%	gavo-cel TC-510	1 PR (RECIST PR)	
	NSCLC	62,600	31%	gavo-cel		
	Cholangiocarcinoma	4,000	50%	gavo-cel	Orphan Drug Designation	
	Pancreatic Cancer	38,000	66%	TC-510		
Colorectal Cancer		81,000	55%	TC-510		
	TNBC	15,000	26%	TC-510		



Consistent Tumor Regression in Patients with gavo-cel


Overall Response Rate 25%, Disease Control Rate 81%



	All	gavo-cel + LD
DCR	81%	77%
ORR (independent)	25%	31%
ORR (investigator)	31%	38%
MPM ORR DCR = PR or SD lasting at lease	27% st 3 months	38%



Patient Response and Follow-up as of June 30, 2021






Phase 1 Case Studies

Patient 15 (MPM)

DL5 (5x10⁸/m²) + LD




66-year-old female Relapsed pleural mesothelioma

Failed 4 prior lines of therapy, including nivolumab/ipilimumab and anti-MSLN ADC

✓ Partial Response (RECIST v1.1)

✓ Tumor Regression (55%)

Patient 5 (Ovarian) DL1 (5x10⁷/m²) + LD



70-year-old female High grade, Stage IV serous ovarian cancer


TP53^{R248Q}, CCNE1 amplified, wild type BRCA1/2 Failed 6 prior lines of therapy Platinum resistant

> Partial Response (RECIST v1.1) \checkmark

✓ Tumor Regression (61%)

Patient 2 (MPM)

DL1 (5x10⁷/m²) + LD



Week 3

74-year-old male Epithelioid pleural mesothelioma

Extensive surgery Feb 2018 \rightarrow PD Pembrolizumab Sep 2018 \rightarrow PD Carboplatin/pemetrexed Apr 2019 (x4) \rightarrow PD

✓ Partial Response (RECIST v1.1)

✓ Tumor Regression (67%)

✓ Complete Metabolic Response



Mesothelioma Represents a Significant Market for gavo-cel

- MPM is a devastating disease that is highly aggressive and represents a majority of mesothelioma cases
- Existing treatment options are limited
 - Second-line treatments have limited PFS (2-4 months) and OS (9-12 months) benefit
- Bristol Myers Squibb clinical trial collaboration aims to boost gavo-cel activity with PD-1 inhibitors
- Most advanced mesothelin program with minimal pipeline competition
 - gavo-cel clinical data (ORR 38%) in 6th line compares favorably to established 2nd line treatment




Prevalence

U.S. Population: 1,800 Est. Gavo-cel Opportunity: 1,200

EU Population: 3,000 Est. Gavo-cel Opportunity: 1,900

Mesothelin Expression




Refs: gavo-cel Phase 1/2 clinical trial, Inaguma 2017, SEER Statistics, Morello 2016, Tozbikian 2014



Emerging Competitive Profile with gavo-cel in MPM

gavo-cel in MPM Patients: ORR 38%, PFS 5.9 Months, OS 11.2 Months



Second Line MPM (Post Platinum-Based Frontline Therapy)

Monotherapy	n	ORR (%)	PFS (mo)	OS (mo)
Vinorelbine	98	3.1	4.2	9.3
vs Supportive Care ¹	56	1.8	2.8	9.1
Pembrolizumab	73	22	2.5	10.7
vs Vinorelbine or Gemcitabine ²	71	6	3.4	12.4


1. Fennell et al Phase 2 VIM Study. ASCO 2021

2. Popat et al Phase 3 PROMISE-meso Study. Ann Oncol 2020



MPM, Malignant Pleural/Peritoneal Mesothelioma; ORR, Overall Response Rate; PFS, Progression Free Survival; OS, Overall Survival

Phase 2 Expansion Cohorts in MSLN+ Solid Tumors



Key Objectives

Mesothelin Expression

In Collaboration with

- Primary: ORR (RECIST v1.1), DCR (ORR+SD)
- Secondary: PFS, OS

- MPM and Ovarian: ≥50% 2+/3+
- NSCLC and Cholangio: ≥50% 1+/2+/3+

H Bristol Myers Squibb[™]




Expanding the Base

Innovating the Next Generation of TRuCs



Enhancing gavo-cel with a PD-1:CD28 Switch Receptor


- PD-1:CD28 switch designed to convert PD-L1/L2 inhibitory function into a potent costimulatory signal
- Costimulation occurs only in a PD-L1/2 rich tumor microenvironment upon TRuC and PD-1 ligation resulting in a more targeted signal enhancement
- Mesothelin-targeting TRuCs that co-express a PD-1:CD28 switch in vivo featured:
 - Enhanced early TCR downstream signaling
 - Significantly increased proliferation
 - Prevented exhaustion upon repeated antigen stimulation
 - Enhances efficacy of gavo-cel against PD-L1 overexpressing tumors



Against Tumors with High PD-L1 Expression, TC-510 Shows Enhanced Proliferation and Superior Efficacy

Expansion upon Repeated Stimulation

Anti-Tumor Activity in Mouse Model




MSTO-M/PDL1 model expressing high MSLN and PD-L1



TC-510 Phase 1 Trial in MSLN+ Solid Tumors

PATIENT POPULATION: ≤5 PRIOR LINES OF THERAPY



Key Objectives

Mesothelin Expression


- Primary: Safety, establish RP2D
- Secondary: ORR (RECIST v1.1), DoR, DCR (ORR+SD), PFS, OS
- ≥50% 1+/2+/3+




CD70: Highly Attractive Target with an Innate Fratricide Challenge

Up to 141,000 Patients Expressing CD70 in the US

- Versatile tumor target: expressed in hematological malignancies (AML, lymphoma) and solid tumors (RCC, NSCLC, OC)
 - Expression in normal cells limited to a subset of activated T cells, B cells, and dendritic cells
 - Expression in activated T cells renders CD70-directed T cell therapies susceptible to fratricide
- Clinically validated: POC demonstrated in AML with αCD70 mAb in AML (argenx)
- Path to first-in-class autologous CD70 cell therapy
 - Most advanced CAR-T programs by Allogene and CRISPR are allogeneic targeting RCC




Allo TRuC-T Cells Generated in a Two-Step Process







Equivalent Anti-Tumor Activity of gavo-cel with Allogeneic TRuC-T Cells





Upcoming Milestones

Clinical Programs

July 2022 gavo-cel Phase 1 dataset

- 2H22 Update from gavo-cel Phase 2 trial
- 2H22 Update from TC-510 Phase 1 trial

Pipeline

- 2H22 Initiate IND-enabling studies for TC-520
- 2H22 Lead candidate identification allogeneic program





THE POWER OF Fomorrow

Engaging the TCR to Transform the Treatment of Solid Tumors

- investors@tcr2.com
- partnering@tcr2.com
- info@tcr2.com

Thank You

